FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marco Gottardis

Research Profile

Chemicals & Drugs

Concepts & Ideas

Living Beings

Anatomy

Physiology

Disorders

Prostatic Neoplasms

Genes & Molecular Sequences

Molecular Structure

Co-author Network

Publications

TOP 3
Petra Ross-Macdonald; Anthony Sampognaro; Mark Saulnier; Nathan Siemers; Charles Tilford; George Trainor; Amy Truong; Dolatrai Vyas; Joan Carboni; Heshani de Silva; Marco Dodier; David Frennesson; Marco Gottardis; Ann Greer; Aiqing He; RuiRu Ji; Frank Lee; Krista Menard; Isaac Neuhaus; Vishal Patel; Kurt Zimmermann; Mark Wittman
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.
ASHOK Purandare; Petra Ross-Macdonald; S U Ruepp; T L Taylor; A Tefferi; George L Trainor; R Vuppugalla; Honghe Wan; A Woolfson; D You; Y Zhang; Yuval Blat; H de Silva; S L Emanuel; E Fitzpatrick; Marco Gottardis; X Han; J Hosbach; T L Lasho; F Y Lee; L Lombardo; T M McDevitt; Kim W McIntyre; E Michaud; C Mulligan; A Pardanani; D Pedicord; Becky Penhallow; Matthew V Lorenzi
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.
Carly Jade Dool; Marco Gottardis; Haider Mashhedi; Elena Birman; Marie-José Blouin; Joan M Carboni; Stéphanie David; Mahvash Zakikhani; Yunhua Zhao; Michael Pollak
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marco Gottardis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Petra Ross-Macdonald; Anthony Sampognaro; Mark Saulnier; Nathan Siemers; Charles Tilford; George Trainor; Amy Truong; Dolatrai Vyas; Joan Carboni; Heshani de Silva; Marco Dodier; David Frennesson; Marco Gottardis; Ann Greer; Aiqing He; RuiRu Ji; Frank Lee; Krista Menard; Isaac Neuhaus; Vishal Patel; Kurt Zimmermann; Mark Wittman
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.
Bioorganic & medicinal chemistry 2012;20(6):1961-72.
2012: ASHOK Purandare; Petra Ross-Macdonald; S U Ruepp; T L Taylor; A Tefferi; George L Trainor; R Vuppugalla; Honghe Wan; A Woolfson; D You; Y Zhang; Yuval Blat; H de Silva; S L Emanuel; E Fitzpatrick; Marco Gottardis; X Han; J Hosbach; T L Lasho; F Y Lee; L Lombardo; T M McDevitt; Kim W McIntyre; E Michaud; C Mulligan; A Pardanani; D Pedicord; Becky Penhallow; Matthew V Lorenzi
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.
Leukemia 2012;26(2):280-8.
2011: Carly Jade Dool; Marco Gottardis; Haider Mashhedi; Elena Birman; Marie-José Blouin; Joan M Carboni; Stéphanie David; Mahvash Zakikhani; Yunhua Zhao; Michael Pollak
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Endocrine-related cancer 2011;18(6):699-709.
2011: Hind Medyouf; Oksana Nemirovsky; Francoise Pflumio; Michael Pollak; Andreas Trumpp; Jen-Chieh Tseng; Carol Wai; Hongfang Wang; Jon C Aster; Joan Carboni; Marco Gottardis; Samuel Gusscott; Martin Holzenberger; Andrew L Kung; Andrew P Weng
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.
The Journal of experimental medicine 2011;208(9):1809-22.
2011: William R Foster; Bruce D Car; Hong Shi; Paul C Levesque; Mary T Obermeier; Jinping Gan; Joseph C Arezzo; Stephanie S Powlin; Joseph E Dinchuk; Aaron Balog; Mark E Salvati; Ricardo M Attar; Marco Gottardis
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
The Prostate 2011;71(5):480-8.
2011: Lalgudi S Harikrishnan; Muthoni G Kamau; Honghe Wan; Jennifer A Inghrim; Kurt Zimmermann; Xiaopeng Sang; Harold A Mastalerz; Walter L Johnson; Guifen Zhang; Louis J Lombardo; Michael A Poss; George L Trainor; John S Tokarski; Matthew V Lorenzi; Dan You; Marco Gottardis; Kathy F Baldwin; Jonathan Lippy; David S Nirschl; Ruhui Qiu; Arthur V Miller; Javed Khan; John S Sack; ASHOK Purandare
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
Bioorganic & medicinal chemistry letters 2011;21(5):1425-8.
2011: Dana Elizabeth Rathkopf; Glenn Liu; Michael A Carducci; Mario A Eisenberger; Aseem Anand; Michael J Morris; Susan F Slovin; Yasutsuna Sasaki; Shunji Takahashi; Seiichiro Ozono; Nga Kit Eliza Fung; Shinta Cheng; Jinping Gan; Marco Gottardis; Mary T Obermeier; Jyotsna Reddy; S Zhang; Blisse J Vakkalagadda; Leila Alland; George Wilding; Howard I Scher
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):880-7.
2011: Xiaonan Hou; Fei Huang; Joan M Carboni; Karen Flatten; Yan W Asmann; Cynthia Ten Eyck; Takeo Nakanishi; Jennifer D Tibodeau; Douglas Ross; Marco Gottardis; Charles Erlichman; Scott H Kaufmann; Paul Haluska
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Molecular cancer therapeutics 2011;10(1):117-25.
2010: Joseph E Dinchuk; Carolyn Cao; Fei Huang; Karen A Reeves; Jeanne Wang; Fanny Myers; Glenn H Cantor; Xiadi Zhou; Ricardo M Attar; Marco Gottardis; Joan M Carboni
Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.
Endocrinology 2010;151(9):4123-32.
2010: Upender Velaparthi; Mark G Saulnier; Mark Wittman; Peiying Liu; David B Frennesson; Kurt Zimmermann; Joan M Carboni; Marco Gottardis; Aixin Li; Ann Greer; Wendy Clarke; Zheng Yang; Krista Menard; Francis Y Lee; George Trainor; Dolatrai M Vyas
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.
Bioorganic & medicinal chemistry letters 2010;20(10):3182-5.
2010: Kurt Zimmermann; Mark Wittman; Mark G Saulnier; Upender Velaparthi; Xiaopeng Sang; David B Frennesson; Charles Struzynski; Steven P Seitz; Liqi He; Joan M Carboni; Aixin Li; Ann F Greer; Marco Gottardis; Ricardo M Attar; Zheng Yang; Praveen Balimane; Lorell N Discenza; Francis Y Lee; Michael Sinz; Sean Kim; Dolatrai Vyas
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
Bioorganic & medicinal chemistry letters 2010;20(5):1744-8.
2009: Andrea E Wahner Hendrickson; Paul Haluska; Paula A Schneider; David Loegering; Kevin L Peterson; Ricardo M Attar; B Douglas Smith; Charles Erlichman; Marco Gottardis; Judith E Karp; Joan M Carboni; Scott H Kaufmann
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
Cancer research 2009;69(19):7635-43.
2009: Honghe Wan; Tram Huynh; Suhong Pang; Jieping Geng; Wayne Vaccaro; Michael A Poss; George L Trainor; Matthew V Lorenzi; Marco Gottardis; Lata Jayaraman; ASHOK Purandare
Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.
Bioorganic & medicinal chemistry letters 2009;19(17):5063-6.
2009: Patricia A McDonnell; Joseph Yanchunas; John A Newitt; Li Tao; Susan E Kiefer; Marie Ortega; Stephanie Kut; Neil Burford; Valentina Goldfarb; Gerald J Duke; Henry Shen; William Metzler; Michael Doyle; Zhong Chen; Christine Tarby; Robert M Borzilleri; Wayne Vaccaro; Marco Gottardis; Songfeng Lu; Donald Crews; Kyoung Kim; Louis J Lombardo; Deborah L Roussell
Assessing compound binding to the Eg5 motor domain using a thermal shift assay.
Analytical biochemistry 2009;392(1):59-69.
2009: Tram Huynh; Zhong Chen; Suhong Pang; Jieping Geng; Tiziano Bandiera; Simona Bindi; Paola Vianello; Fulvia Roletto; Sandrine Thieffine; Arturo Galvani; Wayne Vaccaro; Michael A Poss; George L Trainor; Matthew V Lorenzi; Marco Gottardis; Lata Jayaraman; ASHOK Purandare
Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).
Bioorganic & medicinal chemistry letters 2009;19(11):2924-7.
2009: Sofia Avnet; Laura Sciacca; Manuela Salerno; Giovanni Gancitano; Maria Francesca Cassarino; Alessandra Longhi; Mahvash Zakikhani; Joan M Carboni; Marco Gottardis; Armando Giunti; Michael Pollak; Riccardo Vigneri; Nicola Baldini
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.
Cancer research 2009;69(6):2443-52.
2009: Beate C Litzenburger; Hyun-Jung Kim; Isere Kuiatse; Joan M Carboni; Ricardo M Attar; Marco Gottardis; Craig R Fairchild; Adrian V Lee
BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):226-37.
2009: Fei Huang; Ann Greer; Warren Hurlburt; Xia Han; Rameh Hafezi; Gayle M Wittenberg; Karen Reeves; Jiwen Chen; Douglas Robinson; Aixin Li; Francis Y Lee; Marco Gottardis; Edwin Clark; Lee Helman; Ricardo M Attar; Ashok Dongre; Joan M Carboni
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Cancer research 2009;69(1):161-70.
2008: Upender Velaparthi; Mark Wittman; Peiying Liu; Joan M Carboni; Francis Y Lee; Ricardo Attar; Praveen Balimane; Wendy Clarke; Michael W Sinz; Warren Hurlburt; Karishma Patel; Lorell Discenza; Sean Kim; Marco Gottardis; Ann Greer; Aixin Li; Mark Saulnier; Zheng Yang; Kurt Zimmermann; George Trainor; Dolatrai Vyas
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Journal of medicinal chemistry 2008;51(19):5897-900.
2008: Kurt Zimmermann; Mark D Wittman; Mark G Saulnier; Upender Velaparthi; David R Langley; Xiaopeng Sang; David Frennesson; Joan Carboni; Aixin Li; Ann Greer; Marco Gottardis; Ricardo M Attar; Zheng Yang; Praveen Balimane; Lorell N Discenza; Dolatrai Vyas
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(14):4075-80.
2008: Mark E Salvati; Aaron Balog; Weifang Shan; Richard Rampulla; Soren Giese; Toomas Mitt; Joseph A Furch; Gregory D Vite; Ricardo M Attar; Maria Jure-Kunkel; Jieping Geng; Cheryl A Rizzo; Marco Gottardis; Stanley R Krystek; Jack Gougoutas; Michael A Galella; Mary Obermeier; Aberra Fura; Gamini Chandrasena
Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
Bioorganic & medicinal chemistry letters 2008;18(6):1910-5.
2008: Mark G Saulnier; David B Frennesson; Mark Wittman; Kurt Zimmermann; Upender Velaparthi; David R Langley; Charles Struzynski; Xiaopeng Sang; Joan M Carboni; Aixin Li; Ann Greer; Zheng Yang; Praveen Balimane; Marco Gottardis; Ricardo M Attar; Dolatrai M Vyas
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.
Bioorganic & medicinal chemistry letters 2008;18(5):1702-7.
2008: Liang Schweizer; Cheryl A Rizzo; Thomas E Spires; J Suso Platero; Qiuyan Wu; Tai-An Lin; Marco Gottardis; Ricardo M Attar
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
BMC cell biology 2008;9():4.
2007: Howard H Bailey; Dona Alberti; James P Thomas; Daniel Mulkerin; Kim Binger; Marco Gottardis; Robert E Martell; George Wilding
Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3623-9.
2007: Upender Velaparthi; Peiying Liu; Balu N Balasubramanian; Joan M Carboni; Ricardo M Attar; Marco Gottardis; Aixin Li; Ann Greer; Mary Zoeckler; Mark Wittman; Dolatrai M Vyas
Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.
Bioorganic & medicinal chemistry letters 2007;17(11):3072-6.
2007: Upender Velaparthi; Mark Wittman; Peiying Liu; Karen M Stoffan; Kurt Zimmermann; Xiaopeng Sang; Joan M Carboni; Aixin Li; Ricardo M Attar; Marco Gottardis; Ann Greer; ChiehYing Y Chang; Bruce L Jacobsen; John S Sack; Yax Sun; David R Langley; Balu N Balasubramanian; Dolatrai M Vyas
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).
Bioorganic & medicinal chemistry letters 2007;17(8):2317-21.
2007: Hyun-Jung Kim; Beate C Litzenburger; Xiaojiang Cui; David A Delgado; Brian Grabiner; Xin Lin; Michael Lewis; Marco Gottardis; Tze Wai Wong; Ricardo M Attar; Joan M Carboni; Adrian V Lee
Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.
Molecular and cellular biology 2007;27(8):3165-75.
2007: Mark Wittman; Balu N Balasubramanian; Karen M Stoffan; Upender Velaparthi; Pieying Liu; Subramaniam Krishnanathan; Joan M Carboni; Aixin Li; Ann Greer; Ricardo M Attar; Marco Gottardis; Chiehying Chang; Bruce Jacobson; Yax Sun; Steven B Hansel; Mary Zoeckler; Dolatrai M Vyas
Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.
Bioorganic & medicinal chemistry letters 2007;17(4):974-7.
2006: Kyoung Soon Kim; Songfeng Lu; Lyndon A Cornelius; Louis J Lombardo; Robert M Borzilleri; Gretchen M Schroeder; Christopher Sheng; George Rovnyak; Donald Crews; Robert J Schmidt; David K Williams; Rajeev S Bhide; Sarah C Traeger; Patricia A McDonnell; Luciano Mueller; Steven Sheriff; John A Newitt; Andrew T Pudzianowski; Zheng Yang; Robert Wild; Frances Y Lee; Roberta Batorsky; James S Ryder; Marie Ortega-Nanos; Henry Shen; Marco Gottardis; Deborah L Roussell
Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors.
Bioorganic & medicinal chemistry letters 2006;16(15):3937-42.
2006: James M Rae; Michael Johnson; Kevin E Cordero; Joshua O Scheys; Jose M Larios; Marco Gottardis; Kenneth Pienta; Marc Lippman
GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
The Prostate 2006;66(8):886-94.
2006: Christine M Tarby; Robert F Kaltenbach; Tram Huynh; Andrew T Pudzianowski; Henry Shen; Marie Ortega-Nanos; Steven Sheriff; John A Newitt; Patricia A McDonnell; Neil Burford; Craig R Fairchild; Wayne Vaccaro; Zhong Chen; Robert M Borzilleri; Joseph Naglich; Louis J Lombardo; Marco Gottardis; George L Trainor; Deborah L Roussell
Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series.
Bioorganic & medicinal chemistry letters 2006;16(8):2095-100.
2006: Brian E Fink; Ashvinikumar V Gavai; John S Tokarski; Bindu Goyal; Raj Misra; Hai-yun Xiao; S David Kimball; Wen-Ching Han; Derek Norris; Thomas E Spires; Dan You; Marco Gottardis; Matthew V Lorenzi; Gregory D Vite
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Bioorganic & medicinal chemistry letters 2006;16(6):1532-6.
2006: Paul Haluska; Joan M Carboni; David Loegering; Francis Y Lee; Mark Wittman; Mark G Saulnier; David B Frennesson; Kimberly R Kalli; Cheryl A Conover; Ricardo M Attar; Scott H Kaufmann; Marco Gottardis; Charles Erlichman
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Cancer research 2006;66(1):362-71.
2005: Thomas E Spires; Brian E Fink; Ellen K Kick; Dan You; Cheryl A Rizzo; Ivone Takenaka; R Michael Lawrence; Zheming Ruan; Mark E Salvati; Gregory D Vite; roberto weinmann; Ricardo M Attar; Marco Gottardis; Matthew V Lorenzi
Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
The Prostate 2005;65(2):159-70.
2005: Joan M Carboni; Adrian V Lee; Darryl L Hadsell; Bruce R Rowley; Francis Y Lee; David K Bol; Amy Camuso; Marco Gottardis; Ann Greer; Ching Ping Ho; Warren Hurlburt; Aixin Li; Mark G Saulnier; Upender Velaparthi; Cindy Wang; Mei-Li Wen; Richard A Westhouse; Mark Wittman; Kurt Zimmermann; Brent A Rupnow; Tze Wai Wong
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.
Cancer research 2005;65(9):3781-7.
2005: Mark E Salvati; Aaron Balog; Donna D Wei; Dacia Pickering; Ricardo M Attar; Jieping Geng; Cheryl A Rizzo; John T Hunt; Marco Gottardis; roberto weinmann; Rogelio Martinez
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.
Bioorganic & medicinal chemistry letters 2005;15(2):389-93.
2005: Mark E Salvati; Aaron Balog; Weifang Shan; Donna D Wei; Dacia Pickering; Ricardo M Attar; Jieping Geng; Cheryl A Rizzo; Marco Gottardis; roberto weinmann; Stanley R Krystek; John S Sack; Yongmi An; Kevin Kish
Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.
Bioorganic & medicinal chemistry letters 2005;15(2):271-6.
2004: Aaron Balog; Mark E Salvati; Weifang Shan; Arvind Mathur; Leslie Leith; Donna D Wei; Ricardo M Attar; Jieping Geng; Cheryl A Rizzo; Chihuei Wang; Stanley R Krystek; John S Tokarski; John T Hunt; Marco Gottardis; roberto weinmann
The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists.
Bioorganic & medicinal chemistry letters 2004;14(24):6107-11.
2003: Valerie Vivat Hannah; William Bourguet; Marco Gottardis; Hinrich Gronemeyer
Separation of retinoid X receptor homo- and heterodimerization functions.
Molecular and cellular biology 2003;23(21):7678-88.
2003: Chihuei Wang; Fan Yeung; Po-Chun Liu; Ricardo M Attar; Jieping Geng; Leland W K Chung; Marco Gottardis; Chinghai Kao
Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen.
The Journal of biological chemistry 2003;278(34):32423-30.
2003: Kevin D Houston; John A Copland; Russell R Broaddus; Marco Gottardis; Susan M Fischer; Cheryl Lyn Walker
Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma.
Cancer research 2003;63(6):1221-7.
2002: Wolfgang Raffelsberger; Doulaye Dembélé; Mike G Neubauer; Marco Gottardis; Hinrich Gronemeyer
Quality indicators increase the reliability of microarray data.
Genomics 2002;80(4):385-94.
2001: Valerie Vivat Hannah; Dan You; C Rizzo; Jean-Paul Daris; Philippe Lapointe; F Christopher Zusi; Anne Marinier; Matthew V Lorenzi; Marco Gottardis
Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel).
Cancer research 2001;61(24):8703-11.
2000: S D Gamage; Eric D Bischoff; KD Burroughs; William W Lamph; Marco Gottardis; C L Walker; Robin Fuchs-Young
Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
The Journal of pharmacology and experimental therapeutics 2000;295(2):677-81.
2000: K Wu; Heung Tae Kim; J L Rodriquez; Debbie Munoz-Medellin; Syed K Mohsin; Susan G Hilsenbeck; William W Lamph; Marco Gottardis; M A Shirley; John Kuhn; Jeffrey E Green; Powel H Brown
9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3696-704.
1999: Deborah S Hunter; Leslie C Hodges; P M Vonier; Robin Fuchs-Young; Marco Gottardis; Cheryl Lyn Walker
Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium.
Cancer research 1999;59(13):3090-9.
1998: Eric D Bischoff; Marco Gottardis; T E Moon; Richard A Heyman; William W Lamph
Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
Cancer research 1998;58(3):479-84.